BNCM wow this is getting exciting BNCM Announces Game-Changing Management Transfer to DELEX Group!
Press Release | 01/13/2025
January 2025 The Big News!
Big things are happening at BNCM! The company has officially joined forces with DELEX Group, marking the start of a thrilling new chapter in its journey. The management transfer process is set to be completed by March 2025, and it promises to supercharge BNCM's growth under the leadership of DELEX. Heres a closer look at the bold moves and exciting plans ahead:
A New Era Begins: Management Transfer Kicks Off
The transition to DELEX Groups management begins this month, and its all systems go. Throughout this shift, the talented BNCM team will continue to play a vital role, ensuring smooth operations and a seamless handover of responsibilities as the new leadership steps in.
A Bold New Share Structure
With DELEX now holding a dominant 59.25% majority stake, BNCM is poised for incredible growth. The remaining shares (15.75% for BNCM and 25% for the public and other shareholders) will keep the companys future in diverse and dynamic hands. The finalized share structure will be unveiled in the upcoming Q4 report.
Meet the Dream Team: DELEXs Powerhouse Management
DELEX is bringing in a team thats already proven its success. The new management team is packed with seasoned professionals who have led DELEX Pharma to new heights for over 15 years. These top-tier executives will now drive BNCMs future success.
Key Members of the Team:
New Chairman J. de Ruyter Coching Oroceo
New COO Noel Lagare Omandam
New CFO Ana Lyn Pascual Matienzo
New CMO Ma. Lourdes Elvira Primavera Monasterio
New CTO Melandrino Manarpaac Diego
Hatadi Supaat has agreed to remain as CEO for BNCM for the next 6 months and as Corporate Advisor for several months to ensure a smooth transition and focus on the Investor Relations (IR) campaign for BNCM which he strongly believes needs to be done aggressively with an experienced IR team.
Investor Relations Campaign: Get Ready for Action!
BNCM is about to take the investment world by storm. The upcoming IR campaign is set to break new ground, utilizing cutting-edge digital marketing, AI technology, and innovative branding strategies. This campaign will boost BNCMs market visibility, attract investors, enhance stakeholder confidence, and ultimately drive shareholder returns to new heights.
Ambitious Expansion Plans: The Skys the Limit!
DELEXs aggressive expansion strategy is nothing short of groundbreaking. Over the next five years, theyre targeting huge growth across all facets of the business:
Expanding the FDA-approved product portfolio from 30 to 50.
Growing pharmacy stores from 3 to 60.
Acquiring strategic businesses to fuel growth.
Building a stronger global presence through more ICU forums with healthcare professionals.
Expanding distribution channels from 700 to 1,000 by forging new partnerships with healthcare providers.
Name Change & Ticker Symbol Revamp
Out with the old, in with the new! BNCM will officially apply to change its name to DELEX, alongside an updated ticker symbol, reflecting the bold new direction of the company. Expect big things in Q1 2025!
Regulation A Application: A Step Towards Bigger Growth
DELEX is taking things to the next level by filing a Regulation A application with the SEC starting in March 2025. This move will provide even more opportunities for expansion and growth as DELEX continues to push boundaries.
Uplisting to OTCQB / QX The Journey to NASDAQ
DELEX has its sights set on an OTCQB listing, with a goal to eventually move up to OTCQX and potentially NASDAQ. As the company continues to meet the necessary standards, expect DELEX to make waves in the market!
About DELEX Healthcare Group, Inc. (DELEX)
DELEX is on a mission to revolutionize the pharmaceutical and healthcare industry. As a Delaware-registered company, DELEX partners with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc., bringing high-quality products to market. With a focus on innovation, regulatory excellence, and customer service, DELEX strives to meet the growing demands of the market while adhering to the highest standards of regulatory compliance and customer service excellence.
For more information, visit - https://bncm.net/ zero dilution possible with SS maxed and tiny float BNCM Security Details
Share Structure
Market Cap Market Cap
24,795,287
01/13/2025
Authorized Shares
2,000,000,000
01/13/2025
Outstanding Shares
1,999,619,885
01/13/2025
Restricted
1,929,131,304
01/13/2025
Unrestricted
70,488,581
01/13/2025
Held at DTC
11,382,620
01/13/2025
Press Release | 01/13/2025
January 2025 The Big News!
Big things are happening at BNCM! The company has officially joined forces with DELEX Group, marking the start of a thrilling new chapter in its journey. The management transfer process is set to be completed by March 2025, and it promises to supercharge BNCM's growth under the leadership of DELEX. Heres a closer look at the bold moves and exciting plans ahead:
A New Era Begins: Management Transfer Kicks Off
The transition to DELEX Groups management begins this month, and its all systems go. Throughout this shift, the talented BNCM team will continue to play a vital role, ensuring smooth operations and a seamless handover of responsibilities as the new leadership steps in.
A Bold New Share Structure
With DELEX now holding a dominant 59.25% majority stake, BNCM is poised for incredible growth. The remaining shares (15.75% for BNCM and 25% for the public and other shareholders) will keep the companys future in diverse and dynamic hands. The finalized share structure will be unveiled in the upcoming Q4 report.
Meet the Dream Team: DELEXs Powerhouse Management
DELEX is bringing in a team thats already proven its success. The new management team is packed with seasoned professionals who have led DELEX Pharma to new heights for over 15 years. These top-tier executives will now drive BNCMs future success.
Key Members of the Team:
New Chairman J. de Ruyter Coching Oroceo
New COO Noel Lagare Omandam
New CFO Ana Lyn Pascual Matienzo
New CMO Ma. Lourdes Elvira Primavera Monasterio
New CTO Melandrino Manarpaac Diego
Hatadi Supaat has agreed to remain as CEO for BNCM for the next 6 months and as Corporate Advisor for several months to ensure a smooth transition and focus on the Investor Relations (IR) campaign for BNCM which he strongly believes needs to be done aggressively with an experienced IR team.
Investor Relations Campaign: Get Ready for Action!
BNCM is about to take the investment world by storm. The upcoming IR campaign is set to break new ground, utilizing cutting-edge digital marketing, AI technology, and innovative branding strategies. This campaign will boost BNCMs market visibility, attract investors, enhance stakeholder confidence, and ultimately drive shareholder returns to new heights.
Ambitious Expansion Plans: The Skys the Limit!
DELEXs aggressive expansion strategy is nothing short of groundbreaking. Over the next five years, theyre targeting huge growth across all facets of the business:
Expanding the FDA-approved product portfolio from 30 to 50.
Growing pharmacy stores from 3 to 60.
Acquiring strategic businesses to fuel growth.
Building a stronger global presence through more ICU forums with healthcare professionals.
Expanding distribution channels from 700 to 1,000 by forging new partnerships with healthcare providers.
Name Change & Ticker Symbol Revamp
Out with the old, in with the new! BNCM will officially apply to change its name to DELEX, alongside an updated ticker symbol, reflecting the bold new direction of the company. Expect big things in Q1 2025!
Regulation A Application: A Step Towards Bigger Growth
DELEX is taking things to the next level by filing a Regulation A application with the SEC starting in March 2025. This move will provide even more opportunities for expansion and growth as DELEX continues to push boundaries.
Uplisting to OTCQB / QX The Journey to NASDAQ
DELEX has its sights set on an OTCQB listing, with a goal to eventually move up to OTCQX and potentially NASDAQ. As the company continues to meet the necessary standards, expect DELEX to make waves in the market!
About DELEX Healthcare Group, Inc. (DELEX)
DELEX is on a mission to revolutionize the pharmaceutical and healthcare industry. As a Delaware-registered company, DELEX partners with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc., bringing high-quality products to market. With a focus on innovation, regulatory excellence, and customer service, DELEX strives to meet the growing demands of the market while adhering to the highest standards of regulatory compliance and customer service excellence.
For more information, visit - https://bncm.net/ zero dilution possible with SS maxed and tiny float BNCM Security Details
Share Structure
Market Cap Market Cap
24,795,287
01/13/2025
Authorized Shares
2,000,000,000
01/13/2025
Outstanding Shares
1,999,619,885
01/13/2025
Restricted
1,929,131,304
01/13/2025
Unrestricted
70,488,581
01/13/2025
Held at DTC
11,382,620
01/13/2025
